Ignite Creation Date:
2024-05-06 @ 1:39 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01863147
Status:
COMPLETED
Last Update Posted:
2015-08-18
First Post:
2013-05-21
Brief Title:
Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Sponsor:
Wuhan General Hospital of Guangzhou Military Command
Organization:
Wuhan General Hospital of Guangzhou Military Command
Study Overview
Official Title:
Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cardiovascular complications account for the highest mortality in type 2 diabetic patients mainly due to coronary artery disease CADLeft ventricular hypertrophy LVH is widespread in type 2 diabetic patients with CAD even in the absence of hypertension It is a strong predictor of cardiovascular events and all-cause mortality
Sitagliptin an inhibitor of dipeptidyl peptidase-4 DPP-4 may regress left ventricular mass LVM in newly diagnosed type 2 diabetic patients with CAD
Sitagliptin an inhibitor of dipeptidyl peptidase-4 DPP-4 may regress left ventricular mass LVM in newly diagnosed type 2 diabetic patients with CAD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None